Viz HCM flags hypertrophic cardiomyopathy in a 61-year-old

AI system

System: Viz HCM
Model: Not assessed
Release: Not assessed
Application developer: Viz.ai
Role: Not assessed
Configuration: Not assessed
Inputs and outputs: Not assessed
Autonomy: Not assessed
Workflow: Uploading routine 12-lead ECGs to the Viz HCM cloud platform as an institutional initiative. A referral pathway from AI flag to a specialist HCM center.
Human oversight: Not assessed
Relation to AI: The AI-ECG probability (>0.95) was the trigger for referral and echocardiography in a patient not previously suspected of HCM. Imaging confirmed the diagnosis and clinicians chose the treatment. Disclosed relationships: Dr Desai is a consultant for and has research agreements with Viz-ai (among other companies). Mrs Rutkowski is a consultant for Viz-ai. Mrs Ospina has none. All three authors are listed under the Cleveland Clinic Hypertrophic Cardiomyopathy Center, with no Viz.ai affiliation.
AI contribution: The AI-ECG probability (>0.95) was the trigger for referral and echocardiography in a patient not previously suspected of HCM. Imaging confirmed the diagnosis and clinicians chose the treatment. Disclosed relationships: Dr Desai is a consultant for and has research agreements with Viz-ai (among other companies). Mrs Rutkowski is a consultant for Viz-ai. Mrs Ospina has none. All three authors are listed under the Cleveland Clinic Hypertrophic Cardiomyopathy Center, with no Viz.ai affiliation.

Studies: Not assessed
Study design: Not assessed
Measurement: Not assessed
Setting and sample: Not assessed
Measures: by week 8 the resting gradient was 9 mm Hg
Comparison: the clinical reading of the same baseline ECG
Results: Reference: interpreted clinically as normal sinus rhythm with first-degree atrioventricular block. Result: a high probability score (>0.95) for HCM.
Additional value from AI: Not assessed
Limitations: Not assessed
Denominators: Not assessed
Materials for replication: Not assessed

Participants: Developer: Viz.ai. Operator: Cleveland Clinic.
Jurisdictions: Benefit: Cleveland, United States. Developer: United States. Operator: United States.
Ownership and control: Not assessed
Dependencies: Not assessed
Cross-border connections: Not assessed
Geopolitical implications: Not assessed

Conditions for replication: Echocardiographic confirmation before treatment. Access to mavacamten with REMS monitoring.
Replication attempts: Not assessed
Later findings: The case report ends at week 8 of mavacamten; no later development appears in the cited source.
Availability: Not assessed
Institutional decision: Not assessed
Grounds: Not assessed
Action and result: Not assessed
Success criterion: Not assessed

Assessed benefits: People.
Depth: People: 3.
Reasons: People: An undiagnosed obstructive cardiomyopathy causing dizziness and exertional limitation was identified and treated with a disease-specific drug. Gradient reduction and symptom improvement at 8 weeks are documented. Long-term benefit is not yet shown.
Observed or intended: Not assessed
Rubric: Not assessed
Assessor and date: Not assessed
Alternative assessments: Not assessed
Fill: The deployer's account

Kind: Not assessed
Related entries: Not assessed
Field: Healthcare - cardiology. AI-ECG screening in a health system.
Purpose: Viz HCM is a cloud-based AI-ECG algorithm built to flag probable hypertrophic cardiomyopathy from 12-lead ECGs. This diagnosis is its intended function.
Dates: Date basis unassessed: 2025 (precision unassessed). Updated: 21 October 2026.
Stage: Not assessed
Version: SHA-256: d83b61a0b89d…